T-DXd confirmed as preferred second-line therapy for metastatic HER2-positive breast cancer
Last Updated: Friday, July 17, 2026
According to updated data from the phase III DESTINY-Breast03 trial—presented during the 2022 San Antonio Breast Cancer Symposium—second-line fam-trastuzumab deruxtecan-nxki (T-DXd) significantly improved progression-free survival (P < .000001) and overall survival (P = .0037), compared with ado-trastuzumab emtansine (T-DM1), among patients with unresectable or metastatic HER2-positive breast cancer.